Clinical trials: Diabetes Type I
Type 1 Diabetes Mellitus
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1…
- Trial name
- NCT02500979
- Testing
- Pramlintide acetate, Lispro insulin U-100, Regular insulin U-100
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
The trial was conducted in Germany, The Republic of Macedonia, Russian Federation, Serbia and South Africa. The aim of this trial was to make a safety comparison of insulin detemir produced by a new production method (NN729) with…
- Trial name
- NCT00447382
- Testing
- insulin detemir, insulin aspart
- Where
- 5 sites in Germany, North Macedonia and 3 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
To evaluate non-inferiority in the efficacy of HMR1964 as compared with Insulin lispro in terms of the change in HbA1C from baseline to endpoint. To compare the safety of HMR1964 with insulin lispro.
- Trial name
- NCT00290979
- Testing
- insulin glulisine
- Where
- Japan
- Volunteers
- 250 people
- Sponsor
- Sanofi
Type 1 Diabetes
Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes
The main objective is to determine the efficacy of Lyumjev (insulin) in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1.
- Trial name
- FAST 1 (NCT05508061)
- Testing
- Insulin Lispro Cartridge [Lyumjev], Insulin Lispro Cartridge
- Where
- 3 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Inreda Diabetic B.V.
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion.
- Trial name
- DEFEND-1 (NCT00678886)
- Testing
- otelixizumab infusion plus physician determined standard of care
- Where
- 109 sites in United States, Canada and 7 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Diabetic Peripheral Neuropathy
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild…
- Trial name
- NCT01681290
- Testing
- CBX129801
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Cebix Incorporated
Type 1 Diabetes, Type 2 Diabetes
Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References
The purpose of the study is to prospectively evaluate a noninvasive, near-infrared based method for measuring glucose concentration relative to invasive blood reference measurements.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes
- Trial name
- NCT01415544
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Type 1 Diabetes
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with type 1 diabetes on postprandial plasma glucose concentrations
- Trial name
- NCT01708044
- Testing
- Pramlintide acetate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes.
- Trial name
- ONWARDS 11 (NCT07076199)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 182 sites in United States, Australia and 6 more
- Volunteers
- 877 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Sleep Quality
Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus
The purpose of this research is to evaluate the effect of a wearable insulin pump on blood sugar levels during sleep. The study device works with continuous glucose monitors (CGM) to calculate and deliver rapid-acting insulin…
- Trial name
- AID4MDI (NCT06627517)
- Testing
- Episodic overnight patch pump
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Luna Diabetes
Diabetes Mellitus, Type 1
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works
This study is designed to investigate the movement of insulin NNC0363-0845 throughout the body and how it works for the treatment of type 1 diabetes mellitus.
- Trial name
- NCT05134987
- Testing
- NNC0363-0845, Insulin detemir
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Non-insulin-dependent Diabetes Mellitus
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
This is a phase IIIb, randomised, double blind, placebo controlled, study in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension. The total duration of the study will be approximately 60 weeks.
- Trial name
- NCT00231387
- Testing
- rosiglitazone
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Registry for Stage 2 Type 1 Diabetes
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually…
- Trial name
- NCT06481904
- Testing
- TZIELD (teplizumab-mzwv)
- Where
- 37 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese patients with type 1 diabetes…
- Trial name
- EDITION JP I (NCT01689129)
- Testing
- Insulin glargine new formulation (HOE901), Insulin glargine (HOE901) (Lantus)
- Where
- 22 sites in Japan
- Volunteers
- 243 people
- Sponsor
- Sanofi
Type I Diabetes
Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients
This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's Recombinant Insulin Analogue with the innovator's Glargine in Type 1 diabetics patients.
- Trial name
- NCT01352663
- Testing
- Wockhardt's Insulin Analogue (Recomb), Lantus®
- Sponsor
- Wockhardt
Diabetes, Diabetes Melletus, Type 1
ROME GS System Study
The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.
- Conditions
- Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT07518004
- Testing
- Continuous Glucose Monitoring System
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Senseonics, Inc.
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 620G and 640G Insulin Pumps
This six center international study will include two United Kingdom National Health Service centers, two centers in Melbourne, Australia and one center each in Denmark and Spain.
- Trial name
- NCT01726621
- Testing
- Medtronic MiniMed 620G or 640G Insulin Pump
- Where
- 6 sites in Australia, Denmark and 2 more
- Volunteers
- 55 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System
The purpose of this study is to evaluate the safety and effectiveness of the MEDTRUM Hybrid Closed Loop (HCL) System in children, adolescents, and adults with type 1 diabetes (7-75 years old) in a home setting and to test the…
- Trial name
- SEECLOOP (NCT06363916)
- Testing
- Insulin Management System in Manual mode of operation, Insulin Management System in Automatic mode of operation
- Where
- 17 sites in France
- Volunteers
- 160 people
- Sponsor
- Medtrum France
Diabetes, Diabetes Mellitus, Type 1
Paediatric Subjects - Special Survey
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01538576
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
This observational study is conducted in Europe. The trial aims to observe the incidence of serious adverse drug reactions in children and adolescents with type 1 diabetes during Levemir® treatment.
- Trial name
- PREDICTIVE™ (NCT00704574)
- Testing
- insulin detemir
- Where
- Sweden
- Volunteers
- 159 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.